Endocannabinoids and their receptors as targets for treating metabolic and psychiatric disorders

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 4, 2006, Pages 561-567

  Felder, Christian C ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; DRONABINOL; ENDOCANNABINOID; LY 2183240; NABILONE; RIMONABANT; UNCLASSIFIED DRUG; VIRODHAMINE;

ATAXIA; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; DIZZINESS; DRUG EFFICACY; DRUG INDICATION; DRUG STRUCTURE; DRUG TARGETING; DYSPHORIA; GENE ACTIVATION; GENE TARGETING; HUMAN; HYPNOSIS; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INFERTILITY; MENTAL DISEASE; METABOLIC DISORDER; MOOD DISORDER; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PAIN; PROTEIN LOCALIZATION; REVIEW; SEDATION; SIDE EFFECT; STRUCTURE ANALYSIS; TACHYCARDIA; TISSUE DISTRIBUTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 33846125567     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.10.015     Document Type: Review

References (38)

1. Devane W.A., et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34 (1988) 605-613
2. Howlett A.C., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002) 161-202
3. Herkenham M., et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11 (1991) 563-583
4. Herkenham M. Localization of cannabinoid receptors in brain and periphery. In: Pertwee R.G. (Ed). Neuroscience Perspectives; Cannabinoid receptors (1995), Academic Press Ltd/Academic Press, Inc., 14 Belgrave Square, 24-28 Oval Road, London NW1 70X, England, UK/1250 Sixth Ave., San Diego, California 92101 145-166
5. Gong J.P., et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 1071 (2006) 10-23
6. Benito C., et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 23 (2003) 11136-11141
7. Van Sickle M.D., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005) 329-332
8. Mackie K. Cannabinoid Receptors and Their Therapeutic Targets. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 101-122
9. Ligresti A., et al. Endocannabinoid metabolic pathways and enzymes. Curr. Drug Targets - CNS Neurol. Disord. 4 (2005) 615-623
10. Pertwee R.G. Pharmacological and therapeutic targets for DELTA9-tetrahydrocannabinol and cannabidiol. Euphytica 140 (2004) 73-82
11. Goani Y., and Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86 (1964) 1646-1647
12. Matsuda L.A., et al. Cannabinoid ceceptor and functional expression of the cloned complementary DNA. Nature 346 (1990) 561-564
13. Munro S., et al. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
14. Pertwee R. Cannabinoid pharmacology: the first 66 years. Br. J. Pharmacol. 147 (2006) S167-S171
15. Tanda G., and Goldberg S.R. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms-a review of recent preclinical data. Psychopharmacology 169 (2003) 115-134
16. Price M.R., et al. Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharmacol. 68 (2005) 1484-1495
17. Christopoulos A., et al. G-protein-coupled receptor allosterism: the promise and the problem(s). Biochem. Soc. Trans. 32 (2004) 873-877
18. Goutopoulos A., and Makriyannis A. From cannabis to cannabinergics: new therapeutic opportunities. Pharmacol. Ther. 95 (2002) 103-117
19. Ibrahim M.M., et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl. Acad. Sci. U S A 100 (2003) 10529-10533
20. Ofek O., et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Acad. Sci. U S A 103 (2006) 696-701
21. Witkin J.M., et al. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav. Pharmacol. 16 (2005) 315-331
22. Despres J.-P., et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353 (2005) 2121-2134
23. Pavon F.J., et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole - LH 21. Neuropharmacology 51 (2006) 358-366
24. Terranova J.P., et al. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology 126 (1996) 165-172
25. Osei-Hyiaman D., et al. Cocaine- and amphetamine-related transcript is involved in the orexigenic effect of endogenous anandamide. Neuroendocrinology 81 (2005) 273-282
26. Griffin G., et al. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur. J. Pharmacol. 377 (1999) 117-125
27. Di Marzo V., et al. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 3 (2004) 771-784
28. Bradshaw H.B., and Walker J.M. The expanding field of cannabimimetic and related lipid mediators. Br. J. Pharmacol. 144 (2005) 459-465
29. McFarland M.J., and Barker E.L. Anandamide transport. Pharmacol. Ther. 104 (2004) 117-135
30. McKinney M.K., and Cravatt B.F. Structure and function of fatty acid amide hydrolase. Annu. Rev. Biochem. 74 (2005) 411-432
31. Felder C.C., et al. Cannabinoids biology: the search for new therapeutic targets. Mol. Interv. 6 (2006) 149-161
32. Jayamanne A., et al. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br. J. Pharmacol. 147 (2006) 281-288
33. Gaetani S., et al. Anandamide hydrolysis: a new target for anti-anxiety drugs?. Trends Mol. Med. 9 (2003) 474-478
34. Moore S.A., et al. Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc. Natl. Acad. Sci. U S A 102 (2005) 17852-17857
35. Gobbi G., et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. U S A 102 (2005) 18620-18625
36. Gobbi G., et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. U S A 102 (2005) 18620-18625
37. Dickason-Chesterfield A.K., et al. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cell Mol. Neurobiol. (2006) 10.1007/s10571-006-9072-6
38. Simon G.M., and Cravatt B.F. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl Ethanolamine and a role for α/β-hydrolase 4 in this Pathway. J. Biol. Chem. 281 (2006) 26465-26472